Top

BMC Psychiatry

Published in:

01-12-2021 | Obesity | Research

Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study

Authors: Jake Prillo, Jocelyn Fotso Soh, Haley Park, Serge Beaulieu, Outi Linnaranta, Soham Rej

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

Bipolar disorders (BD) are associated with increased prevalence of obesity and metabolic syndrome (MetS). Nevertheless, there is a wide range in prevalence estimates, with little known about the contributions of pharmacotherapy. It has been suggested that lithium might have a more favorable metabolic profile. We hypothesized that lithium use is associated with less increased body mass index (BMI), MetS, and type II diabetes, when compared with non-lithium users (those on anticonvulsants, second-generation antipsychotics).

Methods

Cross-sectional study of 129 patients aged 18–85 with bipolar disorder, followed at tertiary care clinics in Montreal. Patients using lithium were compared with those not on lithium, for body mass index and metabolic syndrome.

Results

The prevalence of obesity and metabolic syndrome in the sample of lithium-using patients with BD was 42.4 and 35.7% respectively, with an average BMI of 29.10 (+/− 6.70). Lithium and non-lithium groups did not differ in BMI or prevalence of MetS. However, compared to the non-lithium group, lithium users had lower hemoglobin A1C (5.24 +/− 0.53 versus 6.01 +/− 1.83, U = 753.5, p = 0.006) and lower triglycerides (1.46 +/− 0.88 versus 2.01 +/− 1.25, U = 947, p = 0.020).

Conclusions

There is a high prevalence of obesity and metabolic syndrome among patients with bipolar disorder. However, this did not appear to be associated with lithium use, when compared to those not on lithium. The lithium subgroup was also associated with lower prevalence of type II diabetes. Future prospective and intervention studies with larger sample sizes are necessary to further explore the association between lithium and insulin resistance, as well as its underlying mechanisms.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. https://doi.org/10.1111/bdi.12609.CrossRefPubMedPubMedCentral

Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2003;64(Suppl 5):44–52.PubMed

McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721–8. https://doi.org/10.1016/S0140-6736(11)61516-X.CrossRefPubMed

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed

Kemp DE, Sylvia LG, Calabrese JR, Nierenberg AA, Thase ME, Reilly-Harrington NA, et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand. 2014;129(1):24–34. https://doi.org/10.1111/acps.12101.CrossRefPubMed

Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105. https://doi.org/10.1002/hup.908.CrossRefPubMed

Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112–7. https://doi.org/10.1176/appi.ajp.160.1.112.CrossRefPubMed

Jin H, McCrone P. Cost-of-illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics. 2015;33(4):341–53. https://doi.org/10.1007/s40273-014-0250-y.CrossRefPubMed

National Collaborating Centre for Mental Health. National Institute for Health and Care Excellence: Clinical Guidelines. Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. London: The British Psychological Society and The Royal College of Psychiatrists. © The British Psychological Society & The Royal College of Psychiatrists, 2014. 2014.

10.

McElroy SL, Keck PE Jr. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep. 2012;14(6):650–8. https://doi.org/10.1007/s11920-012-0313-8.CrossRefPubMed

11.

de Almeida KM, Moreira CL, Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know? CNS Neurosci Ther. 2012;18(2):160–6. https://doi.org/10.1111/j.1755-5949.2011.00240.x.CrossRefPubMed

12.

Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–80. https://doi.org/10.1002/wps.20420.CrossRefPubMedPubMedCentral

13.

Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol. 2010;25(2):60–7. https://doi.org/10.1097/YIC.0b013e328333ac1b.CrossRefPubMed

14.

Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. CNS Drugs. 1998;9(2):135–51. https://doi.org/10.2165/00023210-199809020-00005.CrossRef

15.

Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111–21. https://doi.org/10.4088/JCP.v66n0116.CrossRefPubMed

16.

Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016;13(8):e1002058. https://doi.org/10.1371/journal.pmed.1002058.CrossRefPubMedPubMedCentral

17.

Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442–55. https://doi.org/10.1001/archpsyc.64.4.442.CrossRefPubMed

18.

Lan C-C, Liu C-C, Lin C-H, Lan T-Y, McInnis MG, Chan C-H, et al. A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study. Bipolar Disord. 2015;17(7):705–14. https://doi.org/10.1111/bdi.12336.CrossRefPubMed

19.

Fotso Soh J, Torres-Platas SG, Beaulieu S, Mantere O, Platt R, Mucsi I, et al. Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. BMC Psychiatry. 2018;18(1):227. https://doi.org/10.1186/s12888-018-1793-9.CrossRefPubMedPubMedCentral

20.

Kanagarajan K, Gou K, Antinora C, Buyukkurt A, Crescenzi O, Beaulieu S, et al. Morningness-Eveningness questionnaire in bipolar disorder. Psychiatry Res. 2018;262:102–7. https://doi.org/10.1016/j.psychres.2018.02.004.CrossRefPubMed

21.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–9. https://doi.org/10.1192/bjp.134.4.382.CrossRefPubMed

22.

Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429–35. https://doi.org/10.1192/bjp.133.5.429.CrossRefPubMed

23.

Vincenzi B, Greene CM, Ulloa M, Parnarouskis L, Jackson JW, Henderson DC. Lithium or valproate adjunctive therapy to second-generation antipsychotics and metabolic variables in patients with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2016;22(3):175–82. https://doi.org/10.1097/PRA.0000000000000149.CrossRefPubMedPubMedCentral

24.

Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015;206(1):52–7. https://doi.org/10.1192/bjp.bp.114.152850.CrossRefPubMed

25.

Steardo L Jr, Fabrazzo M, Sampogna G, Monteleone AM, D'Agostino G, Monteleone P, et al. Impaired glucose metabolism in bipolar patients and response to mood stabilizer treatments. J Affect Disord. 2019;245:174–9. https://doi.org/10.1016/j.jad.2018.10.360.CrossRefPubMed

26.

McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126(3):366–87. https://doi.org/10.1016/j.jad.2010.04.012.CrossRefPubMed

27.

Kaidanovich O, Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets. 2002;6(5):555–61. https://doi.org/10.1517/14728222.6.5.555.CrossRefPubMed

28.

Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417(6886):292–5. https://doi.org/10.1038/417292a.CrossRefPubMed

29.

Melo MCA, Abreu RLC, Linhares Neto VB, de Bruin PFC, de Bruin VMS. Chronotype and circadian rhythm in bipolar disorder: a systematic review. Sleep Med Rev. 2017;34:46–58. https://doi.org/10.1016/j.smrv.2016.06.007.CrossRefPubMed

30.

McGuire S, Shields M, Carroll MD, Ogden CL. Adult obesity prevalence in Canada and the United States. NCHS data brief no. 56, Hyattsville, MD: National Center for Health Statistics, 2011. Adv Nutr. 2011;2(4):368–9. https://doi.org/10.3945/an.111.000497.CrossRefPubMedPubMedCentral

31.

Lamontagne P, Hamel D. Surveillance du statut pondéral chez les adultes québécois: Portrait et évolution de 1987 à 2010: Direction de l'analyse et de l'évaluation des systèmes de soins et services …; 2012.

32.

Riediger ND, Clara I. Prevalence of metabolic syndrome in the Canadian adult population. Cmaj. 2011;183(15):E1127–34. https://doi.org/10.1503/cmaj.110070.CrossRefPubMedPubMedCentral

33.

Canadian Health Measures Survey: Cycle 1 data tables. Statistics Canada. 2010. Catalogue no. 82-623-X. ISSN 1920-6550.

34.

Population estimates on July 1st, by age and sex. Statistics Canada. Ottawa, ON2021. p. Table 17-0-0005-01. https://doi.org/10.25318/1710000501-eng.

35.

Tully A, Murphy E, Smyth S, Conway Y, Geddes J, Devane D, et al. Interventions for the management of obesity in people with bipolar disorder. Cochrane Database Syst Rev. 2018;2018(4):CD013006. https://doi.org/10.1002/14651858.CD013006.CrossRefPubMedCentral

36.

Coello K, Vinberg M, Knop FK, Pedersen BK, McIntyre RS, Kessing LV, et al. Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. Int J Bipolar Disord. 2019;7(1):8. https://doi.org/10.1186/s40345-019-0142-3.CrossRefPubMedPubMedCentral

37.

Rej S, Segal M, Low NCP, Mucsi I, Holcroft C, Shulman K, et al. The McGill geriatric Lithium-induced diabetes insipidus clinical study (McGLIDICS). Can J Psychiatr. 2014;59(6):327–34. https://doi.org/10.1177/070674371405900606.CrossRef

38.

Krakauer NY, Krakauer JC. A new body shape index predicts mortality Hazard independently of body mass index. PLoS One. 2012;7(7):e39504. https://doi.org/10.1371/journal.pone.0039504.CrossRefPubMedPubMedCentral

39.

Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666–78. https://doi.org/10.1016/S0140-6736(06)69251-9.CrossRefPubMed

Title: Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study
Authors: Jake Prillo
Jocelyn Fotso Soh
Haley Park
Serge Beaulieu
Outi Linnaranta
Soham Rej
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Obesity
Obesity
Insulins
Antipsychotics
Insulins
Antipsychotics
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03572-w

At a glance: The STEP trials

Springer Medicine

Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Discrepancy between experience and importance of recovery components in the symptomatic and recovery perceptions of people with severe mental disorders

Depressive symptoms among Peruvian adult residents amidst a National Lockdown during the COVID-19 pandemic

ENgage YOung people earlY (ENYOY): a mixed-method study design for a digital transdiagnostic clinical – and peer- moderated treatment platform for youth with beginning mental health complaints in the Netherlands

Verification of using virtual reality to evaluate deficiencies in cognitive function among patients with schizophrenia in the remission stage: a cross-sectional study

The D*Phase-study: study protocol for a pragmatic two-phased, randomised controlled (non-inferiority) trial that addresses treatment non-response and compares cognitive behavioural therapy and short-term psychodynamic supportive psychotherapy for major depression

Taking the LEAP: study protocol for a randomized, multicentre, naturalistic, efficacy trial of the compuLsive Exercise Activity theraPy (LEAP) - a cognitive behavioral program specifically targeting compulsive exercise in patients with eating disorders